{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:19:56Z","timestamp":1791296396404,"version":"4.1.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tissue transglutaminase (TG2) is involved in Ca2+-dependent aggregation and polymerization of proteins. We previously reported that TG2 mRNA is up-regulated in epithelial ovarian cancer (EOC) cells compared with normal ovarian epithelium. Here, we show overexpression of the TG2 protein in ovarian cancer cells and tumors and its secretion in ascites fluid and define its role in EOC. By stable knockdown and overexpression, we show that TG2 enhances EOC cell adhesion to fibronectin and directional cell migration. This phenotype is preserved in vivo, where the pattern of tumor dissemination in the peritoneal space is dependent on TG2 expression levels. TG2 knockdown diminishes dissemination of tumors on the peritoneal surface and mesentery in an i.p. ovarian xenograft model. This phenotype is associated with deficient \u03b21 integrin-fibronectin interaction, leading to weaker anchorage of cancer cells to the peritoneal matrix. Highly expressed in ovarian tumors, TG2 facilitates i.p. tumor dissemination by enhancing cell adhesion to the extracellular matrix and modulating \u03b21 integrin subunit expression. [Cancer Res 2007;67(15):7194\u2013202]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-0307","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T14:34:13Z","timestamp":1185978853000},"page":"7194-7202","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase"],"prefix":"10.1158","volume":"67","author":[{"given":"Minati","family":"Satpathy","sequence":"first","affiliation":[{"name":"1Medicine, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Cao","sequence":"additional","affiliation":[{"name":"1Medicine, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Pincheira","sequence":"additional","affiliation":[{"name":"8Department of Surgery, University of California at San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Emerson","sequence":"additional","affiliation":[{"name":"2Pathology and Laboratory Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bigsby","sequence":"additional","affiliation":[{"name":"3Obstetrics and Gynecology,"},{"name":"6Indiana University Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishna","family":"Nakshatri","sequence":"additional","affiliation":[{"name":"4Surgery, and"},{"name":"5Biochemistry and Molecular Biology;"},{"name":"6Indiana University Cancer Center; and"},{"name":"7Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[{"name":"1Medicine, Departments of"},{"name":"3Obstetrics and Gynecology,"},{"name":"5Biochemistry and Molecular Biology;"},{"name":"6Indiana University Cancer Center; and"},{"name":"7Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2022061623340778100_B1","doi-asserted-by":"crossref","unstructured":"Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev\u20082001; 22: 255\u201388.","DOI":"10.1210\/edrv.22.2.0422"},{"key":"2022061623340778100_B2","doi-asserted-by":"crossref","unstructured":"Auersperg N, Pan J, Grove BD, et al. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A\u20081999; 96: 6249\u201354.","DOI":"10.1073\/pnas.96.11.6249"},{"key":"2022061623340778100_B3","doi-asserted-by":"crossref","unstructured":"Davidson B, Goldberg I, Reich R, et al. \u03b1V- and \u03b21-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol\u20082003; 90: 248\u201357.","DOI":"10.1016\/S0090-8258(03)00321-4"},{"key":"2022061623340778100_B4","doi-asserted-by":"crossref","unstructured":"Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett\u20081995; 91: 229\u201334.","DOI":"10.1016\/0304-3835(95)03743-G"},{"key":"2022061623340778100_B5","doi-asserted-by":"crossref","unstructured":"Ahmed N, Pansino F, Clyde R, et al. Overexpression of \u03b1(v)\u03b26 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis\u20082002; 23: 237\u201344.","DOI":"10.1093\/carcin\/23.2.237"},{"key":"2022061623340778100_B6","doi-asserted-by":"crossref","unstructured":"Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S. \u03b1(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene\u20082003; 22: 1688\u2013702.","DOI":"10.1038\/sj.onc.1206347"},{"key":"2022061623340778100_B7","unstructured":"Casey RC, Skubitz AP. CD44 and \u03b21 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis\u20082000; 18: 67\u201375."},{"key":"2022061623340778100_B8","unstructured":"Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res\u20082001; 61: 4961\u20135."},{"key":"2022061623340778100_B9","unstructured":"Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res\u20081995; 1: 1223\u201332."},{"key":"2022061623340778100_B10","doi-asserted-by":"crossref","unstructured":"Carreiras F, Cruet S, Staedel C, Sichel F, Gauduchon P. Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion. Gynecol Oncol\u20081999; 72: 312\u201322.","DOI":"10.1006\/gyno.1998.5262"},{"key":"2022061623340778100_B11","doi-asserted-by":"crossref","unstructured":"Byers LJ, Osborne JL, Carson LF, et al. Increased levels of laminin in ascitic fluid of patients with ovarian cancer. Cancer Lett\u20081995; 88: 67\u201372.","DOI":"10.1016\/0304-3835(94)03625-S"},{"key":"2022061623340778100_B12","unstructured":"Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for \u03b1(V)\u03b2(3) and \u03b1(V)\u03b2(5) integrins and promotes cell motility. Cancer Res\u20082002; 62: 5358\u201364."},{"key":"2022061623340778100_B13","doi-asserted-by":"crossref","unstructured":"Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet\u20081999; 21: 115\u20138.","DOI":"10.1038\/5063"},{"key":"2022061623340778100_B14","doi-asserted-by":"crossref","unstructured":"Buczek-Thomas JA, Chen N, Hasan T. Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal\u20081998; 10: 55\u201363.","DOI":"10.1016\/S0898-6568(97)00074-0"},{"key":"2022061623340778100_B15","doi-asserted-by":"crossref","unstructured":"Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, Chang DD. Gene expression in epithelial ovarian carcinoma. Oncogene\u20082002; 21: 6289\u201398.","DOI":"10.1038\/sj.onc.1205785"},{"key":"2022061623340778100_B16","unstructured":"Grigoriev MY, Suspitsin EN, Togo AV, et al. Tissue transglutaminase expression in breast carcinomas. J Exp Clin Cancer Res\u20082001; 20: 265\u20138."},{"key":"2022061623340778100_B17","doi-asserted-by":"crossref","unstructured":"Verma A, Wang H, Manavathi B, et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res\u20082006; 66: 10525\u201333.","DOI":"10.1158\/0008-5472.CAN-06-2387"},{"key":"2022061623340778100_B18","doi-asserted-by":"crossref","unstructured":"Martinet N, Bonnard L, Regnault V, et al. In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer. Am J Respir Cell Mol Biol\u20082003; 28: 428\u201335.","DOI":"10.1165\/rcmb.2002-0114OC"},{"key":"2022061623340778100_B19","doi-asserted-by":"crossref","unstructured":"Mishra S, Murphy LJ. Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem\u20082004; 279: 23863\u20138.","DOI":"10.1074\/jbc.M311919200"},{"key":"2022061623340778100_B20","doi-asserted-by":"crossref","unstructured":"Mehta K, Lopez-Berestein G, Moore WT, Davies PJ. Interferon-\u03b3 requires serum retinoids to promote the expression of tissue transglutaminase in cultured human blood monocytes. J Immunol\u20081985; 134: 2053\u20136.","DOI":"10.4049\/jimmunol.134.4.2053"},{"key":"2022061623340778100_B21","doi-asserted-by":"crossref","unstructured":"Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene\u20082006; 25: 3049\u201358.","DOI":"10.1038\/sj.onc.1209324"},{"key":"2022061623340778100_B22","doi-asserted-by":"crossref","unstructured":"Richardson M, Gunawan J, Hatton MW, Seidlitz E, Hirte HW, Singh G. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. Gynecol Oncol\u20082002; 86: 279\u201387.","DOI":"10.1006\/gyno.2002.6760"},{"key":"2022061623340778100_B23","doi-asserted-by":"crossref","unstructured":"Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res\u20082004; 64: 7045\u20139.","DOI":"10.1158\/0008-5472.CAN-04-1800"},{"key":"2022061623340778100_B24","doi-asserted-by":"crossref","unstructured":"Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA\u20081998; 280: 719\u201323.","DOI":"10.1001\/jama.280.8.719"},{"key":"2022061623340778100_B25","doi-asserted-by":"crossref","unstructured":"Tucholski J, Lesort M, Johnson GV. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience\u20082001; 102: 481\u201391.","DOI":"10.1016\/S0306-4522(00)00482-6"},{"key":"2022061623340778100_B26","unstructured":"Arboleda MJ, Lyons JF, Kabbinavar FF, et al. Overexpression of AKT2\/protein kinase B\u03b2 leads to up-regulation of \u03b21 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res\u20082003; 63: 196\u2013206."},{"key":"2022061623340778100_B27","doi-asserted-by":"crossref","unstructured":"Yuan L, Choi K, Khosla C, et al. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther\u20082005; 4: 1293\u2013302.","DOI":"10.1158\/1535-7163.MCT-04-0328"},{"key":"2022061623340778100_B28","doi-asserted-by":"crossref","unstructured":"Antonyak MA, Miller AM, Jansen JM, et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem\u20082004; 279: 41461\u20137.","DOI":"10.1074\/jbc.M404976200"},{"key":"2022061623340778100_B29","doi-asserted-by":"crossref","unstructured":"Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol\u20082003; 4: 140\u201356.","DOI":"10.1038\/nrm1014"},{"key":"2022061623340778100_B30","doi-asserted-by":"crossref","unstructured":"Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-\u03baB in cancer cells: delineation of a novel pathway. Cancer Res\u20082006; 66: 8788\u201395.","DOI":"10.1158\/0008-5472.CAN-06-1457"},{"key":"2022061623340778100_B31","doi-asserted-by":"crossref","unstructured":"Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGF\u03b2-dependent matrix deposition. J Cell Sci\u20082001; 114: 2989\u20133000.","DOI":"10.1242\/jcs.114.16.2989"},{"key":"2022061623340778100_B32","doi-asserted-by":"crossref","unstructured":"Hang J, Zemskov EA, Lorand L, Belkin AM. Identification of a novel recognition sequence for fibronectin within the NH2-terminal \u03b2-sandwich domain of tissue transglutaminase. J Biol Chem\u20082005; 280: 23675\u201383.","DOI":"10.1074\/jbc.M503323200"},{"key":"2022061623340778100_B33","doi-asserted-by":"crossref","unstructured":"Akimov SS, Krylov D, Fleischman LF, Belkin AM. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol\u20082000; 148: 825\u201338.","DOI":"10.1083\/jcb.148.4.825"},{"key":"2022061623340778100_B34","doi-asserted-by":"crossref","unstructured":"Strobel T, Cannistra SA. \u03b21-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol\u20081999; 73: 362\u20137.","DOI":"10.1006\/gyno.1999.5388"},{"key":"2022061623340778100_B35","doi-asserted-by":"crossref","unstructured":"Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of \u03b21 and \u03b1v\u03b23 integrins in ovarian cancer. Gynecol Oncol\u20081995; 58: 216\u201325.","DOI":"10.1006\/gyno.1995.1214"},{"key":"2022061623340778100_B36","doi-asserted-by":"crossref","unstructured":"Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res\u20082005; 11: 3433\u20138.","DOI":"10.1158\/1078-0432.CCR-04-1510"},{"key":"2022061623340778100_B37","doi-asserted-by":"crossref","unstructured":"Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K\/PKB\/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res\u20082005; 65: 1497\u2013504.","DOI":"10.1158\/0008-5472.CAN-04-2940"},{"key":"2022061623340778100_B38","doi-asserted-by":"crossref","unstructured":"Maubant S, Cruet-Hennequart S, Dutoit S, et al. Expression of \u03b1V-associated integrin \u03b2 subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol\u20082005; 36: 119\u201329.","DOI":"10.1007\/s10735-004-4273-0"},{"key":"2022061623340778100_B39","doi-asserted-by":"crossref","unstructured":"Chan BM, Matsuura N, Takada Y, Zetter BR, Hemler ME. In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells. Science\u20081991; 251: 1600\u20132.","DOI":"10.1126\/science.2011740"},{"key":"2022061623340778100_B40","doi-asserted-by":"crossref","unstructured":"Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A\u20082001; 98: 1853\u20138.","DOI":"10.1073\/pnas.98.4.1853"},{"key":"2022061623340778100_B41","doi-asserted-by":"crossref","unstructured":"Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res\u20082007; 67: 1670\u20139.","DOI":"10.1158\/0008-5472.CAN-06-1147"},{"key":"2022061623340778100_B42","unstructured":"Reinmuth N, Liu W, Ahmad SA, et al. \u03b1v\u03b23 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res\u20082003; 63: 2079\u201387."},{"key":"2022061623340778100_B43","doi-asserted-by":"crossref","unstructured":"Khalili P, Arakelian A, Chen G, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther\u20082006; 5: 2271\u201380.","DOI":"10.1158\/1535-7163.MCT-06-0100"},{"key":"2022061623340778100_B44","doi-asserted-by":"crossref","unstructured":"Eble JA, Haier J. Integrins in cancer treatment. Curr Cancer Drug Targets\u20082006; 6: 89\u2013105.","DOI":"10.2174\/156800906776056518"},{"key":"2022061623340778100_B45","doi-asserted-by":"crossref","unstructured":"Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2 and its substrates in human diseases. Front Biosci\u20082006; 11: 1758\u201373.","DOI":"10.2741\/1921"},{"key":"2022061623340778100_B46","unstructured":"Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res\u20081997; 57: 5416\u201320."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7194\/2866163\/7194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7194\/2866163\/7194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T13:00:25Z","timestamp":1683982825000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/15\/7194\/533314\/Enhanced-Peritoneal-Ovarian-Tumor-Dissemination-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":46,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-0307","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22367241","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367244.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367244","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367247","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367241.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367247.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495477.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495477","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}